The Latest Cardiac and Vascular News
FUROSCIX demonstrated 99.6% bioavailability and produced similar diuresis and natriuresis compared to intravenous furosemide Commercial launch planned in Q1 2023 BURLINGTON, Mass., Oct. 10, 2022 (GLOBE NEWSWIRE) — scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of […]
MORRISVILLE, N.C., Oct. 10, 2022 (GLOBE NEWSWIRE) — Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announces the presentation of positive data from a study of PH-HFpEF patients being treated with […]
Sotatercept demonstrated significant improvement in exercise capacity and key secondary outcome measures compared to placebo when added to background therapy RAHWAY, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive top-line results from the pivotal Phase 3 STELLAR trial evaluating the safety […]
Internationally, the signing of licensing or distribution partnerships with major players in nutrition and healthcare. In France, Valbiotis has chosen to internalize its commercial operations for direct distribution, in order to generate rapid turnover and to ensure an independent and value-creating source of income. Continued structuring and R&D efforts on […]
KFAR-SABA, Israel and IRVINE, Calif., Oct. 6, 2022 /PRNewswire/ — CathWorks announced today the approval of the fourth generation CathWorks FFRangio® System by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). The FFRangio System is also commercially available in the United States and Europe. “The FFRangio System enables us to quickly perform a comprehensive physiologic assessment of coronary artery […]
RANCHO CUCAMONGA, Calif., Oct. 6, 2022 /PRNewswire/ — After treatment and discharge from the emergency room (ER) for congestive heart failure complications, Inland Empire Health Plan (IEHP) member Lavinia experienced panic and anxiety attacks that compounded her heart issues and led to more hospital visits. IEHP team members identified Lavinia’s specialized needs […]
Kaiser Permanente Center for Thoracic Aortic Disease study confirms low long-term risk for most aneurysms OAKLAND, Calif., Oct. 5, 2022 /PRNewswire/ — A large, new Kaiser Permanente study provides high-quality evidence that most of the 33,000 patients diagnosed each year in the U.S. with a thoracic aortic aneurysm — a bulge in […]
Traditional Care: More than 50% Discharged From Hospital With Suboptimal Treatment Oak Ridge, TN, Oct. 04, 2022 (GLOBE NEWSWIRE) — Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces new data from the Mayo Clinic in Rochester, NY validating the benefits of the Company’s BVA-100 blood test for patients with […]
This is the first study to investigate the safety and tolerability of NR in a randomized, placebo-controlled trial of patients with heart failure, marking a milestone for future clinical research LOS ANGELES–(BUSINESS WIRE)–ChromaDex Corp. (NASDAQ:CDXC) today announced promising findings from a clinical study, as reported in the peer-reviewed journal Journal of […]
Company also announces publication of the PROACTIVE-HF trial design rationale, the first global IDE trial for PA pressure-guided heart failure management, in the Journal of Cardiac Failure LISLE, Ill., Sept. 30, 2022 /PRNewswire/ — Endotronix, Inc., a privately-held digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced […]
